Prescribing cascades of antigout medications from thiazide diuretics in gout-naïve hypertensive adults receiving first-line pharmacological management

• Published in: Scientific reports Vol. 14; no. 1; p. 7402
• Main Authors: Lu, Shang-Yeh, Hsu, Hsing-Yu, Hsieh, Yow-Wen, Lu, Chiung-Ray, Huang, Hsin-Yi, Chang, Shih-Sheng
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 28.03.2024; Nature Portfolio
• Subjects: Adult; Angiotensin; Angiotensin II; Angiotensin-converting enzyme inhibitors; Antihypertensive Agents - therapeutic use; Antihypertensives; Calcium Channel Blockers - therapeutic use; Calcium channels; Comorbidity; Comparative analysis; Diuretics; Diuretics - therapeutic use; Drug therapy; Enzyme inhibitors; Gout; Gout - complications; Gout - drug therapy; Gout Suppressants - therapeutic use; Humans; Hypertension; Hypertension - chemically induced; Hypertension - drug therapy; Hypertension - epidemiology; Patients; Peptidyl-dipeptidase A; Population studies; Prescribing cascade; Regression analysis; Retrospective Studies; Sodium Chloride Symporter Inhibitors - therapeutic use; Thiazide; Thiazides - therapeutic use; Hypertension; Thiazide; Gout; Prescribing cascade
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-58153-0

Prescribing cascade is a significant clinical problem but is often overlooked. We explore the incidence of the prescribing cascades of antigout medications related to thiazide treatment in gout-naïve hypertensive adults newly exposed to the pharmacological treatment. This population-based, retrospective cohort study used the Taiwan National Health Insurance Registry Database. Gout-naïve hypertensive adults who were newly dispensed first-line antihypertensive drugs between January 1, 2000, and December 31, 2016, were enrolled. Patients were divided into the thiazide group (n = 4192) and the non-thiazide group (n = 81,083). The non-thiazide group included patients who received an angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, calcium channel blocker, or beta-blocker. The study utilized propensity score matching and multivariable Cox regression models to investigate the prescribing cascade of antigout agents following antihypertensive treatment, adjusting for factors like age, sex, comorbidities, and concurrent medications. After propensity score matching, each group consisted of 4045 patients, with the thiazide group exhibiting a higher risk of being prescribed antigout medications across different time intervals post-treatment initiation. Specifically, adjusted hazard ratios (aHRs) for the thiazide group were 2.23, 2.07, and 2.41 for < 30 days, 31-180 days, and > 180 days, respectively, indicating a sustained and significant risk over time. Comparative analyses revealed thiazide diuretics were associated with a higher risk of antigout medication prescriptions compared to other antihypertensive classes, particularly evident after 180 days. Subgroup analyses across various demographics and comorbidities consistently showed an increased risk in the thiazide cohort. Gout-naïve hypertensive adults newly dispensed thiazide had a higher risk of subsequently adding antigout agents than those taking other first-line antihypertensive medications. The awareness and interruption of these prescribing cascades are critical to improving patient safety.